CSS
AVTX icon

Cubist Systematic Strategies’s Avalo Therapeutics AVTX Stock Holding History

Cubist Systematic Strategies’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-2
Closed -$3K – 4416
2022
Q2 		$3K Buy
2
+1
+100% +$1.34K ﹤0.01% 4307
2022
Q1 		$3K Buy
+1
New +$2.51K ﹤0.01% 3511
2021
Q2 		– Sell
-7
Closed -$57K – 2916
2021
Q1 		$57K Buy
+7
New +$66.1K ﹤0.01% 2724
2020
Q4 		– Sell
-4
Closed -$26K – 2554
2020
Q3 		$26K Sell
4
-7
-64% -$52.6K ﹤0.01% 2405
2020
Q2 		$86K Buy
+11
New +$79.9K ﹤0.01% 2219

Other funds holding AVTX

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return

Cubist Systematic Strategies's AVTX Position: Q3 2022 in Review

Cubist Systematic Strategies sold out of Avalo Therapeutics (AVTX) in Q3 2022, closing a stake of 2 shares — an estimated $3K sold.

Cubist Systematic Strategies first reported a position in AVTX in Q2 2020 and held it in 5 quarters. The position peaked at $86K in Q2 2020. 18 funds tracked by Wall St. Rank hold AVTX as of Q3 2022.

  • Cubist Systematic Strategies reported no remaining Avalo Therapeutics position as of Q3 2022 after selling out during the quarter.
  • Cubist Systematic Strategies sold 2 Avalo Therapeutics shares in Q3 2022, an estimated $3K.
  • Cubist Systematic Strategies first reported a position in Avalo Therapeutics in Q2 2020 and held it in 5 quarters.
  • Cubist Systematic Strategies's Avalo Therapeutics position peaked at $86K in Q2 2020.
  • 18 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q3 2022.

Based on Cubist Systematic Strategies's 13F filing for Q3 2022, filed 14 Nov 2022.